Multicenter evaluation of the antimicrobial activity for six broad- spectrum β-lactams in Venezuela using the Etest method. The Venezuelan Antimicrobial Resistance Study Group.
Multicenter evaluation of the antimicrobial activity for six broad- spectrum β-lactams in Venezuela using the Etest method. The Venezuelan Antimicrobial Resistance Study Group. by Pfaller MA, Jones RN and Doern GV published in Diagn. Microbiol. Infect. Dis 1998; 30 (1): 45-52
National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic.
National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. by Pfaller MA, Jones RN, Messer SA, Edmond MB and Wenzel RP published in Diagn. Microbiol. Infect. Dis. 1998; 30 (2): 121-129
In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi.
In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. by Pfaller MA, Marco F, Messer SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 30 (4): 251-255
National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program.
National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program. by Pfaller MA, Jones RN, Messer SA, Edmond MB and Wenzel RP published in Diagn. Microbiol. Infect. Dis. 1998; 31 (1): 327-332
Hospital specificity, region specificity, and fluconazole resistance of Candida albicans bloodstream isolates.
Hospital specificity, region specificity, and fluconazole resistance of Candida albicans bloodstream isolates. by Pfaller MA, Lockhart SR, Pujol C, Swails-Wenger JA, Messer SA, Edmond MB, Jones RN, Wenzel RP and Soll DR published in J. Clin. Microbiol. 1998; 36 (6): 1518-1529
International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group.
International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. by Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ and Messer SA published in J. Clin. Microbiol. 1998; 36 (7): 1886-1889
Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997).
Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). by Pfaller MA, Jones RN, Doern GV and Kugler K published in Antimicrob. Agents. Chemother. 1998; 42 (7): 1762-1770
In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.
In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. by Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME and Hajjeh RA published in Antimicrob. Agents Chemother. 1998; 42 (12): 3242-3244
In vitro activity of cefepime and other broad-spectrum β-lactams tested against 129 mec A-negative Staphylococcus spp. isolates: A multicenter sample.
In vitro activity of cefepime and other broad-spectrum β-lactams tested against 129 mec A-negative Staphylococcus spp. isolates: A multicenter sample. by Marshall SA, Wilke WW, Chen YS, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 30 (1): 65-69
Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: Frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program.
Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: Frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program. by Marshall SA, Wilke WW, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 30 (3): 205-214
In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. by Marco F, Pfaller MA, Messer S and Jones RN published in Antimicrob. Agents Chemother. 1998; 42 (1): 161-163
In vitro activity of a new triazole antifungal agent, SCH56592, against clinical isolates of filamentous fungi.
In vitro activity of a new triazole antifungal agent, SCH56592, against clinical isolates of filamentous fungi. by Marco F, Pfaller MA, Messer SA and Jones RN published in Mycopathologia 1998; 141 (2): 73-77
Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. by Marco F, Pfaller MA, Messer SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 32 (1): 33-37
Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi.
Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. by Marco F, Pfaller MA, Messer SA and Jones RN published in Med. Mycol. 1998; 36 (6): 433-436
Antimicrobial activity and spectrum investigation of eight broad-spectrum β-lactam drugs: A 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.
Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: A 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group. by Jones RN, Pfaller MA, Doern GV, Erwin ME and Hollis RJ published in Diagn. Microbiol. Infect. Dis. 1998; 30 (3): 215-228
In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis. by Jones RN, Ballow CH, Schentag JJ, Johnson DM and Deinhart JA published in Diagn. Microbiol. Infect. Dis. 1998; 31 (1): 313-325
Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. by Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA and Schentag JJ published in Diagn. Microbiol. Infect. Dis. 1998; 31 (3): 437-451
Epidemiology, laboratory detection, and therapy of penicillin-resistant streptococcal infections.
Epidemiology, laboratory detection, and therapy of penicillin-resistant streptococcal infections. by Jones RN and Wilson WR published in Diagn. Microbiol. Infect. Dis. 1998; 31 (3): 453-459
Important and emerging β-lactamase-mediated resistances in hospital-based pathogens: The Amp-C enzymes.
Important and emerging β-lactamase-mediated resistances in hospital-based pathogens: The Amp-C enzymes. by Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 31 (3): 461-466
Combinations of orally administered β-lactams to maximize spectrum and activity against drug-resistant respiratory tract pathogens: I. Synergy studies of amoxicillin and cefixime with Streptococcus pneumoniae.
Combinations of orally administered β-lactams to maximize spectrum and activity against drug-resistant respiratory tract pathogens: I. Synergy studies of amoxicillin and cefixime with Streptococcus pneumoniae. by Jones RN and Johnson DM published in Diagn. Microbiol. Infect. Dis. 1998; 31 (2): 373-376
Bacterial resistance: A worldwide problem.
Bacterial resistance: A worldwide problem. by Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 1998; 31 (2): 379-388
Current susceptibilities of staphylococci to glycopeptides determined as part of an international resistance surveillance programme. SENTRY Antimicrobial Surveillance Program.
Current susceptibilities of staphylococci to glycopeptides determined as part of an international resistance surveillance programme. SENTRY Antimicrobial Surveillance Program. by Jones ME, Jones RN, Sader H, Verhoef J and Acar J published in J. Antimicrob. Chemother. 1998; 42 (1): 119-121
In vitro evaluation of a novel orally administered cephalosporin (cefditoren) tested against 1,249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.
In vitro evaluation of a novel orally administered cephalosporin (cefditoren) tested against 1,249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. by Jones RN, Biedenbach DJ, Croco MA and Barrett MS published in Diagn. Microbiol. Infect. Dis. 1998; 31 (4): 573-578
In vitro susceptibility testing and quality control parameters for sarafloxacin (A-56620): A fluoroquinolone used for treatment and control of colibacillosis in poultry. Quality Control Study Group.
In vitro susceptibility testing and quality control parameters for sarafloxacin (A-56620): A fluoroquinolone used for treatment and control of colibacillosis in poultry. Quality Control Study Group. by Jones RN and Erwin ME. published in Diagn. Microbiol. Infect. Dis. 1998; 32 (1): 55-64
Activity of a broad-spectrum cephalosporin (RO 48-8391) alone and in combination with two novel β-lactamase inhibitors (RO 48-5545 and RO 48-8724).
Activity of a broad-spectrum cephalosporin (RO 48-8391) alone and in combination with two novel β-lactamase inhibitors (RO 48-5545 and RO 48-8724). by Jones RN, Marshall SA and Varnam DJ published in Diagn. Microbiol. Infect. Dis. 1998; 32 (2): 85-94
Evaluation of the Vitek system to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime.
Evaluation of the Vitek system to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime. by Jones RN, Biedenbach DJ, Marshall SA, Pfaller MA and Doern GV published in Diagn. Microbiol. Infect. Dis. 1998; 32 (2): 107-110
Comparative antimicrobial activity of trovafloxacin tested against 3,049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season.
Comparative antimicrobial activity of trovafloxacin tested against 3,049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season. by Jones RN, Pfaller MA and Doern GV published in Diagn. Microbiol. Infect. Dis. 1998; 32 (2): 119-126
Antimicrobial activity of gatifloxacin tested against 1,676 strains of ciprofloxacin-resistant Gram-positive cocci isolated from patient infections in North and South America.
Antimicrobial activity of gatifloxacin tested against 1,676 strains of ciprofloxacin-resistant Gram-positive cocci isolated from patient infections in North and South America. by Jones RN, Beach ML, Pfaller MA and Doern GV published in Diagn. Microbiol. Infect. Dis. 1998; 32 (3): 247-252
Comparative in vitro activity of alexomycin (U-82127) tested against Escherichia coli, Salmonella spp. and enterococci of animal and human origin.
Comparative in vitro activity of alexomycin (U-82127) tested against Escherichia coli, Salmonella spp. and enterococci of animal and human origin. by Jones RN, Chen YS and Marshall SA published in Clin. Microbiol. Infect. 1998; 4 (10): 601-603
In-vitro activity of a combination of two oral β-lactams (cefpodoxime and amoxycillin) against Streptococcus pneumoniae isolates with reduced susceptibilities to penicillin.
In-vitro activity of a combination of two oral β-lactams (cefpodoxime and amoxycillin) against Streptococcus pneumoniae isolates with reduced susceptibilities to penicillin. by Johnson DM and Jones RN. published in J. Antimicrob. Chemother. 1998; 42 (4): 555-557
Antimicrobial interactions of trovafloxacin and extended-spectrum cephalosporins or azithromycin tested against clinical isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Antimicrobial interactions of trovafloxacin and extended-spectrum cephalosporins or azithromycin tested against clinical isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia. by Johnson DM, Jones RN and Pfaller MA published in J. Antimicrob. Chemother. 1998; 42 (4): 557-559
Molecular analysis of TN1546 in Enterococcus faecium isolated from animals and humans.
Molecular analysis of TN1546 in Enterococcus faecium isolated from animals and humans. by Jensen LB, Ahrens P, Dons L, Jones RN, Hammerum AM and Aarestrup FM published in J. Clin. Microbiol. 1998; 36 (2): 437-442
International multicenter investigation of LB20304, a new fluoronaphthyridone.
International multicenter investigation of LB20304, a new fluoronaphthyridone. by Hohl AF, Frei R, Punter V, von Graevenitz A, Knapp C, Washington J, Johnson D and Jones RN published in Clin. Microbiol. Infect. 1998; 4 (5): 280-284
Multicenter evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group.
Multicenter evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group. by Doern GV, Jones RN, Pfaller MA, Erwin M and Ramirez-Rhonda C published in Diagn. Microbiol. Infect. Dis. 1998; 30 (2): 113-119
Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY Antimicrobial Surveillance Program.
Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. by Doern GV, Pfaller MA, Kugler K, Freeman J and Jones RN published in Clin. Infect. Dis. 1998; 27 (4): 764-770
The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada – 1997 results from the SENTRY Antimicrobial Surveillance Program.
The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada – 1997 results from the SENTRY Antimicrobial Surveillance Program. by Doern GV, Pfaller MA, Erwin ME, Brueggemann AB and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 32 (4): 313-316
Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: Report from the SENTRY Antimicrobial Surveillance Program (1998).
Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: Report from the SENTRY Antimicrobial Surveillance Program (1998). by DiPersio JR, Jones RN, Barrett T, Doern GV and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 1998; 32 (2): 131-135
In vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp.
In vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp. by Croco MA, Biedenbach DJ, Pfaller MA, Doern GV, and Jones RN published in J. Antimicrob. Chemother. 1998; 42 (5): 672-673
In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates.
In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates. by Cormican M, Corbett-Feeney G, Kelly S, Hughes D, Flynn J, and Jones RN published in Ir. J. Med. Sci. 1998; 167 (3): 155-159
Use of molecular and reference susceptibility testing methods in a multicenter evaluation of MicroScan dried overnight Gram-positive MIC panels for detection of vancomycin and high-level aminoglycoside resistances in enterococci.
Use of molecular and reference susceptibility testing methods in a multicenter evaluation of MicroScan dried overnight Gram-positive MIC panels for detection of vancomycin and high-level aminoglycoside resistances in enterococci. by Chen YS, Marshall SA, Winokur PL, Coffman SL, Wilke WW, Murray PR, Spiegel CA, Pfaller MA, Doern GV, and Jones RN published in J. Clin. Microbiol. 1998; 36 (10): 2996-3001
Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains.
Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains. by Biedenbach DJ, Barrett MS and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 31 (2): 349-353
BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens.
BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens. by Biedenbach DJ, Barrett MS, Croco MA, and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 32 (1): 45-50
Antimicrobial activity of gatifloxacin tested against Neisseria gonorrhoeae using three methods and a collection of fluoroquinolone-resistant strains.
Antimicrobial activity of gatifloxacin tested against Neisseria gonorrhoeae using three methods and a collection of fluoroquinolone-resistant strains. by Biedenbach DJ, Beach ML and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 32 (4): 307-311
Timed kill kinetic studies of levofloxacin, ofloxacin, and ciprofloxacin against Moraxella catarrhalis.
Timed kill kinetic studies of levofloxacin, ofloxacin, and ciprofloxacin against Moraxella catarrhalis. by Barrett MS and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 30 (2): 135-137
Multicenter laboratory evaluation of the bioMerieux Vitek antimicrobial susceptibility testing system with 11 antimicrobial agents versus members of the family Enterobacteriaceae and Pseudomonas aeruginosa.
Multicenter laboratory evaluation of the bioMerieux Vitek antimicrobial susceptibility testing system with 11 antimicrobial agents versus members of the family Enterobacteriaceae and Pseudomonas aeruginosa. by Doern GV, Brueggemann AB, Perla R, Daly J, Halkias D, Jones RN and Saubolle MA published in J. Clin. Microbiol. 1997; 35 (8): 2115-2119
A cluster of serious Escherichia coli infections in a neonatal intensive care unit.
A cluster of serious Escherichia coli infections in a neonatal intensive care unit. by Diekema DJ, Barr J, Boyken LD, Buschelman BJ, Jones RN, Pfaller MA and Herwaldt LA published in Infect. Control Hosp. Epidemiol. 1997; 18 (11): 774-776
Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone.
Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. by Cormican MG and Jones RN published in Antimicrob. Agents Chemother. 1997; 41 (1): 204-211
Avoparcin, a glycopeptide used in animal foods: Antimicrobial spectrum and potency tested against human isolates from the United States.
Avoparcin, a glycopeptide used in animal foods: Antimicrobial spectrum and potency tested against human isolates from the United States. by Cormican MG, Erwin ME and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 29 (4): 241-248
Validation of Etest for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices.
Validation of Etest for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices. by Biedenbach DJ, Schermer IH and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 27 (1-2): 1-5
Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents.
Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents. by Biedenbach DJ and Jones RN published in J. Clin. Microbiol. 1997; 35 (12): 3198-3202
